ARTICLE | Clinical News

IMR-687: Ph I started

December 6, 2016 7:59 PM UTC

Imara began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate oral IMR-687 in about 42 healthy volunteers. Imara has exclusive, worldwide rights to IMR-687 from H. Lundbeck (see BioCe...

BCIQ Company Profiles

H. Lundbeck A/S

Imara Inc.

BCIQ Target Profiles

Phosphodiesterase-9 (PDE-9)